logo
Advocates raise awareness for ovarian cancer in Fairmont

Advocates raise awareness for ovarian cancer in Fairmont

Yahoo09-05-2025

FAIRMONT, W.Va. (WBOY) — May 8 is World Ovarian Cancer Awareness Day, and in Fairmont, advocates took time to hang teal balloons in front of the courthouse to raise awareness of the disease.
The teal balloons have become something of a tradition for Kelli Bledsoe, an ovarian cancer survivor whose mother passed from the disease, as this is the fourth year that she's hung up the balloons.
'The more I can tell people about ovarian cancer and what to do,' Bledsoe told 12 News. 'The more lives we can save. The earlier detection, more lives saved.'
Man who fell from stands at Pittsburgh Pirates game speaks out: 'I'm all right'
The World Ovarian Cancer Coalition reported in 2020 that 200,000 women died of the disease that year and that it's tricky to recognize ovarian cancer as its symptoms, like bloating and abdominal pain, can be mistaken for other ailments.
Advocates in Fairmont called for the public to get genetically tested for ovarian cancer in order to help with early detection. Mutations to the BRCA1 and BRCA2 genes are known to lead to an increased risk of ovarian and breast cancer.
The World Ovarian Cancer Coalition has reported that up to 25% of those diagnosed with ovarian cancer had a hereditary tendency to develop the disease.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge

Yahoo

timea day ago

  • Yahoo

‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge

The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.

Rapid Review Quiz: Ovarian Cancer Screening and Prevention
Rapid Review Quiz: Ovarian Cancer Screening and Prevention

Medscape

time3 days ago

  • Medscape

Rapid Review Quiz: Ovarian Cancer Screening and Prevention

Reliably screening for ovarian cancer in the general population remains a challenge. Common tools such as CA-125 testing and transvaginal ultrasound have shown limited sensitivity and specificity, leading to unnecessary surgeries and false reassurance. However, advances in genetic testing and molecular pathology have reshaped prevention strategies, particularly in individuals at elevated hereditary risk such as BRCA mutation carriers. Risk-reducing salpingo-oophorectomy remains the cornerstone of prevention for high-risk patients, while oral contraceptives offer a risk-reducing effect in the general population. Additionally, genetic counseling has become an essential step in identifying at-risk individuals who may benefit from tailored interventions. How much do you know about recent developments in ovarian cancer screening and prevention? Test your knowledge with this updated review. Despite significant research efforts, no screening strategy has yet demonstrated a mortality benefit in average-risk female patients. As noted in the National Comprehensive Cancer Network (NCCN) guidelines, landmark clinical trials — including the PLCO (Prostate, Lung, Colorectal, and Ovarian) cancer screening trial — failed to show a survival benefit from annual CA-125 testing or transvaginal ultrasound alone or in combination. The risk of ovarian cancer algorithm (ROCA) — which evaluates CA-125 trends over time — did improve early-stage detection rates but did not ultimately reduce mortality. As a result, current guidelines from the United States Preventive Services Task Force and other expert bodies, including the NCCN, recommend against routine screening for ovarian cancer in asymptomatic, average-risk females. Instead, attention has shifted toward identifying and managing high-risk individuals through genetic counseling and risk-reducing strategies. Routine screening in the general population is considered ineffective and may result in harms from false-positive tests and unnecessary surgical interventions. Learn more about the workup for ovarian cancer. Risk-reducing salpingo-oophorectomy (RRSO) remains the most effective strategy for preventing ovarian and fallopian tube cancer in individuals with BRCA1 or BRCA2 mutations. Guidelines recommend RRSO typically between ages 35 and 45, depending on the specific mutation and family history. This surgery significantly lowers the risk of high-grade serous carcinoma, the most common and aggressive subtype. Studies have shown that RRSO can reduce ovarian cancer risk significantly also confer a survival benefit, particularly in BRCA1 carriers. While oral contraceptives also reduce risk, they do not offer the same degree of protection as surgical removal of at-risk tissue. Annual pelvic exams and imaging have not demonstrated efficacy in early detection or mortality reduction in this population. Patients considering RRSO should be counseled about surgical menopause and may require hormone therapy depending on age and symptom burden. The procedure is essential in the preventive care of high-risk individuals. Learn more more about ovarian cancer deterrence and prevention. Emerging evidence over the past decade suggests that the fallopian tube epithelium — not the ovary — is the origin of many high-grade serous ovarian carcinomas. As a result, the practice of opportunistic salpingectomy — removing the fallopian tubes during hysterectomy or tubal sterilization procedures — has gained traction as a preventive strategy, even in females at average risk. Major gynecologic societies now endorse this practice as a safe and effective risk-reducing option during pelvic surgery for benign indications. The rationale is grounded in the theory of serous tubal intraepithelial carcinoma as a precursor lesion to high-grade serous cancer. Unlike endometrial cancer, whose origin lies in the uterine lining, salpingectomy directly targets the tissue where most serous carcinomas are thought to begin. Learn more about ovarian cancer and surgical considerations. Current guidelines recommend genetic counseling and consideration of BRCA and multigene panel testing in females with a personal or strong family history of breast, ovarian, fallopian tube, or peritoneal cancer. Identifying carriers of pathogenic variants enables implementation of life-saving risk-reducing strategies, including salpingo-oophorectomy or enhanced surveillance. Importantly, such testing is also offered to individuals with male relatives who have had breast cancer, early-onset cancers, or known mutations in cancer susceptibility genes. Genetic testing should ideally be preceded by counseling to interpret results accurately and discuss implications for family members. Patients with unrelated gynecologic conditions like endometriosis or abnormal uterine bleeding, and those without relevant family history, are not routinely offered genetic testing unless other risk factors emerge. Early identification of mutation carriers is essential for tailored management, timely preventive interventions, and cascade testing of at-risk relatives. Learn more about risk assessment and genetic counseling in ovarian cancer. Multiple large observational studies and meta-analyses have consistently demonstrated a protective effect of combined oral contraceptives (COCs) against ovarian cancer. The reduction in risk is observed with long-term use, typically over 5 years, and persists for decades after discontinuation. The proposed mechanism involves suppression of ovulation, thereby reducing the repetitive trauma and repair cycles to the ovarian epithelium, which may underlie carcinogenesis. The protective effect spans multiple histologic subtypes, including high-grade serous, endometrioid, and clear cell carcinomas. While other agents such as NSAIDs have been evaluated, their protective role is less well established and not considered standard for chemoprevention. Aromatase inhibitors and bisphosphonates are not used for ovarian cancer prevention. As with any medication, the decision to use oral contraceptives must consider individual risk profiles, including thromboembolic and cardiovascular risks, and be guided by patient preferences and shared decision-making. Learn more about ovarian cancer and the impact of oral contraceptives.

NIOSH division in charge of screening for miner lung diseases restored
NIOSH division in charge of screening for miner lung diseases restored

Yahoo

time4 days ago

  • Yahoo

NIOSH division in charge of screening for miner lung diseases restored

MORGANTOWN, (WBOY) — Several jobs at the National Institute of Occupational Safety and Health (NIOSH) in Morgantown have been officially restored following certification earlier this week that Reductions in Force (RIF) at the institution would not happen. So what's next? On Monday, the U.S. Department of Health and Human Services sent out a court document certifying that the RIFs have been rescinded, a move that fully restores the Respiratory Health Division (RHD). This move is in compliance with a court injunction ordered in mid-May as part of a larger case against the cuts. The plaintiff's original suit sought the restoration of RHD, saying that RHD facilitates federally mandated coal miner lung screening programs and job transfer rights. The plaintiff's legal counsel, Samuel Petsonk, told 12 News that even despite this restoration, he is still concerned that NIOSH still doesn't have the ability to perform all of its federally mandated services as well as it did before the RIFs. He added that his office and client are weighing their options. Elderly and disabled residents trapped without functioning elevator in Clarksburg apartment building The rescinded RIFs for RHD accounted for 51 RHD employees, while hundreds of other NIOSH employees were originally impacted. The President of the American Federation of Government Employees (AFGE) Local 3430 Cathy Tinney-Zara, which represents the Morgantown NIOSH office, told 12 News that they were pleased with this rescinding of the RIFs, but that there are components of NIOSH still missing, such as the Health Effects Laboratory Division, which does research focused on evaluating, controlling, and preventing workplace safety and health hazards. Tinney-Zara added that AFGE is waiting for the Supreme Court decision on the broader legality of the federal downsizing. In the statement to 12 News, she said: 'While we await the court's decision, we are ready to return to work and continue our mission of protecting the health and safety of America's workers. We firmly believe that the value we provide to the government, to workers, and to their families will be recognized.' Tinney-Zara added that NIOSH's efforts 'significantly' reduce financial burdens on the federal government by lowering Social Security payments, workers' compensation claims and healthcare expenses. She said that 'by keeping the workforce safer and healthier, we not only save money but also safeguard lives.' You can read the full document certifying the restoration of RHD below. show_multidocsDownload Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store